Respiratory Syncytial Virus (RSV) is a common virus that can cause serious respiratory illness in infants and young children. It is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in infants and young children, which can result in hospitalisation. Preterm infants are at particularly high risk of hospitalisation with an RSV infection. There are no vaccines available to prevent RSV infection. Currently there is a medication to prevent RSV, but it is usually reserved for infants who have serious heart or lung disease, and some premature infants born at less than 28 weeks gestation.
Purpose of the study
This study is being done to evaluate how effective a new medication (called MEDI8897) is at preventing serious respiratory illness caused by RSV in preterm infants.
Who can take part?
Healthy infants who were born preterm at 29 to 35 weeks and born from 1 June 2016.
What does the study involve?
Participation for approximately 1 year
6 to 7 visits to the study clinic, at Princess Margaret Hospital and the Perth Children’s Hospital
1 injection of the study medication or placebo (the same way that baby vaccines are given into the thigh)
4 blood tests
Follow up of any respiratory illnesses that occur during this time
Who has approved the study?
This study has been approved by the Ethics Committees of Princess Margaret Hospital and St John of God Health Care.
Study status: Recruiting in April and May 2017.
Who to contact for more information:
Please contact the study staff at the Vaccine Trials Group, Telethon Kids Institute